These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16245958)

  • 1. Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events.
    van Iersel MB; Zuidema SU; Koopmans RT; Verhey FR; Olde Rikkert MG
    Drugs Aging; 2005; 22(10):845-58. PubMed ID: 16245958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis.
    Yunusa I; Alsumali A; Garba AE; Regestein QR; Eguale T
    JAMA Netw Open; 2019 Mar; 2(3):e190828. PubMed ID: 30901041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials.
    Seibert M; Mühlbauer V; Holbrook J; Voigt-Radloff S; Brefka S; Dallmeier D; Denkinger M; Schönfeldt-Lecuona C; Klöppel S; von Arnim CAF
    Alzheimers Res Ther; 2021 Jul; 13(1):131. PubMed ID: 34271969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?
    Herrmann N; Lanctôt KL
    Drug Saf; 2006; 29(10):833-43. PubMed ID: 16970508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia.
    Gareri P; De Fazio P; Manfredi VG; De Sarro G
    J Clin Psychopharmacol; 2014 Feb; 34(1):109-23. PubMed ID: 24158020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials.
    Ma H; Huang Y; Cong Z; Wang Y; Jiang W; Gao S; Zhu G
    J Alzheimers Dis; 2014; 42(3):915-37. PubMed ID: 25024323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].
    Zuidema SU; van Iersel MB; Koopmans RT; Verhey FR; Olde Rikkert MG
    Ned Tijdschr Geneeskd; 2006 Jul; 150(28):1565-73. PubMed ID: 16886695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review.
    Lee PE; Gill SS; Freedman M; Bronskill SE; Hillmer MP; Rochon PA
    BMJ; 2004 Jul; 329(7457):75. PubMed ID: 15194601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review.
    Pratt N; Roughead EE; Salter A; Ryan P
    BMC Med Res Methodol; 2012 Jun; 12():72. PubMed ID: 22682666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings.
    Bullock R
    Curr Med Res Opin; 2005 Jan; 21(1):1-10. PubMed ID: 15881470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances.
    Schulze J; van den Bussche H; Glaeske G; Kaduszkiewicz H; Wiese B; Hoffmann F
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1034-42. PubMed ID: 23498307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    Ballard C; Waite J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia.
    Zaudig M
    Drug Saf; 2000 Sep; 23(3):183-95. PubMed ID: 11005702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Atypical antipsychotics in elderly patients with dementia].
    Selbaek G; Engedal K
    Tidsskr Nor Laegeforen; 2008 May; 128(9):1060-1. PubMed ID: 18451888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of atypical antipsychotics for behavioral symptoms of dementia among patients residing in long-term care.
    Sturm AS; Trinkley KE; Porter K; Nahata MC
    Int J Clin Pharm; 2018 Feb; 40(1):135-142. PubMed ID: 29189977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.
    Trifiró G; Sultana J; Spina E
    Drug Saf; 2014 Jul; 37(7):501-20. PubMed ID: 24859163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia.
    Carson S; McDonagh MS; Peterson K
    J Am Geriatr Soc; 2006 Feb; 54(2):354-61. PubMed ID: 16460391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of Long-Term Antipsychotic Drug Use for Behavioral and Psychological Symptoms in Older Adults Aged 65 Years and Older With Dementia.
    Van Leeuwen E; Petrovic M; van Driel ML; De Sutter AI; Stichele RV; Declercq T; Christiaens T
    J Am Med Dir Assoc; 2018 Nov; 19(11):1009-1014. PubMed ID: 30100234
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.